Uncover key connections between risks and returns, for richer insights into asset development and commercial opportunities. Determine which drugs have the best chance of success. Project R&D costs, drug pricing, and time-to-market like never before, all with the insight and precision that only Evaluate Omnium can offer.
Omnium combines a range of analytics, including product-specific PTRS, success rate benchmarks, development timelines, R&D costs and the clinical trials landscape to gain deeper development insight.
Better predict commercial outcomes and pinpoint the assets that will drive your growth. With predicted peak sales, indication benchmarks, pricing, NPV modeling and interactive visualizations, you can effectively predict the value of key pipeline assets.
Apply machine learning to data points across the full clinical pipeline to deliver more accurate forecasts, transforming your ability to accurately understand the development risks and returns of key assets, how they affect one another, and what drives them.
Leverage predicted Net Present Value (NPV) by indication that covers 8x more NPV models for R&D programs that aren’t usually covered by existing consensus forecasts. Improve your understanding of product value drivers.
Combine product-specific Probability of Technical & Regulatory Success (PTRS) and predicted peak sales analytics to provide a single metric to forecast the commercial potential of pharma assets across all phases of clinical development. Predict ROI at product indication, product, and company level.
By applying machine learning to millions of data points from across the full clinical pipeline – including early phase and privately held assets – Evaluate Omnium identifies key risk and return correlations that uncover unique, highly accurate insights into asset development and commercial opportunity
Get in touch with our team to explore the right solutions for your business.
